Randomized control trial of interferon-β injections at 12-h intervals as a therapy for chronic hepatitis C

Hepatology Research

Volumn 12, Issue 3, 1998, Pages 240-251

  Fujiwara, Kenji ^a   Mochida, Satoshi ^a   Matsuo, Shu Ichi ^a   Ogata, Itsuro ^b   Hayashi, Shigeki ^c   Sato, Yuzuru ^d  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^d KANTO ROSAI HOSPITAL   (Japan)

Author keywords

Chronic hepatitis; Hepatitis C virus; Interferon

Indexed keywords

ALANINE AMINOTRANSFERASE; BETA INTERFERON;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; THROMBOCYTOPENIA;

EID: 0031712657     PISSN: 09284346     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1386-6346(98)00072-2     Document Type: Article

References (15)

1. Imai Y, Kawata S, Tamura S et al. Recombinant interferon a-2a for treatment of chronic hepatitis C: Results of a multicenter randomized controlled dose study. Liver. 17:1997;88-92.
2. Mochida S, Ohnishi K, Matsuo S et al. Effect of alcohol intake on the efficacy of interferon therapy in patients with chronic hepatitis C as evaluated by multivariate logistic regression analysis. Alcohol Clin Exp Res. 20:1996;371A-377.
3. Hagiwara H, Hayashi N, Kasahara A et al. Long-term biochemical and virological response to natural interferon α in patients with chronic hepatitis C. Dig Dis Sci. 41:1996;1001-1007.
4. Yokosuka O, Kato N, Hosoda K et al. Efficacy of long-term interferon treatment in chronic liver disease evaluated by sensitive polymerase chain assay for hepatitis C virus RNA. Gut. 37:1995;721-726.
5. Yamada G, Takatani M, Kishi F et al. Efficacy of interferon α therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level. Hepatology. 22:1995;1351-1354.
6. Orito E, Mizokami M, Suzuki K et al. Loss of serum HCV-RNA at week 4 of interferon α therapy is associated with more favorable long-term response in patients with chronic hepatitis C. J Med Virol. 46:1995;109-115.
7. Iino S, Hino K, Kuroki T et al. Treatment of chronic hepatitis C with high-dose interferon α-2b. A multicenter study. Dig Dis Sci. 38:1993;612-618.
8. Kobayashi Y, Watanabe S, Konishi M et al. Quantitation and typing of serum hepatitis C virus RNA in patients with chronic hepatitis C treated with interferon β Hepatology. 18:1993;1319-1325.
9. Koyama Y. Pharmacokinetics and clinical trials of HuIFN-β in malignant tumor. In: Kishida T, editor. INTERFERONS. Proceedings of the International Symposium on Interferons. Osaka: Japan Convention Service, 1983:1-7.
10. Weiner AJ, Kuo G, Bradley DW et al. Detection of hepatitis C virus sequences in non-A non-B hepatitis. Lancet. 335:1990;1-3.
11. Ishiyama N, Katayama K, Ishimi N et al. Quantitative detection of hepatitis C virus RNA by multicyclic RT-PCR. Int Hepatol Commun. 1:1993;72-79.
12. Gilliland G, Perrin S, Blanchard K et al. Analysis of cytokine mRNA and DNA: Detection and quantitation by competitive polymerase chain reaction. Proc Natl Acad Sci USA. 87:1990;2725-2729.
13. Okamoto H, Sugiyama Y, Okada S et al. Typing of hepatitis C virus by polymerase chain reaction with two-specific primers: Application to clinical survey and tracing infectious sources. J Gen Virol. 73:1992;673-679.
14. SAS Institute. SAS/STAT Software: Change and Enhancement Release 6.07. Cary, NC, SAS Institute, 1992:435-456.
15. Okushin H, Moriii K, Kishi F et al. Efficacy of the combination therapy using twice-a-day IFN-β followed by IFN-α2b in the treatment for chronic hepatitis C. Acta Hepatol Jpn. 38:1997;11-18.